NCCN Tightens Active Surveillance in Prostate Cancer Guidelines


Unlike zoledronic acid, which is administered intravenously and can potentially affect renal function, denosumab is given subcutaneously and does not affect kidney function, he said; as such, it represents a "novel treatment option."

The updated NCCN prostate cancer guidelines are available at Dr. Mohler is a cofounder and chief medical officer of AndroBioSys Inc. in Buffalo, N.Y.


Next Article: